Early Breast Cancer Clinical Trial
Official title:
Evaluation of Axillary Reverse Mapping (ARM) in Clinically Axillary Node Negative Breast Cancer Patients
NCT number | NCT04137744 |
Other study ID # | hazem nour |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 2015 |
Est. completion date | August 2019 |
Verified date | November 2019 |
Source | Zagazig University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
study patients; axillary node negative breast cancer female, 74 patients randomly allocated in two groups each 37 patients , group I , where axillary reverse mapping(ARM) +ve nodes were preserved and axillary lymph node dissection completed.and group II where axillary reverse mapping +ve nodes were taken with axillary lymph node dissection(ALND) primary outcome is histopathological examination of a ARM +ve lymph nodes and volume measurements of the ipsilateral arm for development of lymphedema at 6 ,12 , and 24 months
Status | Completed |
Enrollment | 74 |
Est. completion date | August 2019 |
Est. primary completion date | August 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - clinically free breast cancer - sentinle LN positive Exclusion Criteria: - patients on chemotherapy for breast cancer - recurrent cases after conservative breast surgery - bilateral disease and pregnant cases |
Country | Name | City | State |
---|---|---|---|
Egypt | Zagazig Faculty of Medicine | Zagazig | Sharqya |
Lead Sponsor | Collaborator |
---|---|
Zagazig University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | histopathologic examination of ARM +ve LN | EITHER +VE OR -VE | IMMEDIATE POSTOPERATIVE | |
Primary | ARM LYMPHOEDEMA | INCREASE OF THE ARM VOLUME BY 10% | 2 years postoperative | |
Secondary | restriction of shoulder movement | in comparison to the other side | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04538833 -
GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel
|
Phase 2 | |
Completed |
NCT04436744 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
|
Phase 2 | |
Completed |
NCT02187744 -
A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)
|
Phase 3 | |
Terminated |
NCT01155063 -
Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
|
N/A | |
Recruiting |
NCT03949634 -
Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin(PLD)
|
Phase 3 | |
Active, not recruiting |
NCT05730647 -
Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients
|
||
Terminated |
NCT01919229 -
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
|
Phase 2 | |
Active, not recruiting |
NCT04293393 -
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
|
Phase 2 | |
Completed |
NCT00713141 -
Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer
|
N/A | |
Recruiting |
NCT06341894 -
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06404736 -
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06404463 -
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06435104 -
Aromatherapy in the Treatment of Early Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03520894 -
Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer
|
N/A | |
Completed |
NCT03786198 -
Activity Program During Aromatase Inhibitor Therapy
|
N/A | |
Completed |
NCT01613352 -
Feasibility of Ambulatory Surgery for Early Breast Cancer
|
N/A | |
Completed |
NCT02738970 -
A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)
|
Phase 1 | |
Recruiting |
NCT01792726 -
A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.
|
N/A | |
Completed |
NCT00323479 -
Arthralgia During Anastrozole Therapy for Breast Cancer
|
Phase 4 | |
Completed |
NCT03493854 -
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
|
Phase 3 |